Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
Albany Medical College, Albany, New York, USA.
Dermatol Ther. 2021 Jul;34(4):e14974. doi: 10.1111/dth.14974. Epub 2021 May 22.
The aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, National Psoriasis Foundation, British Association of Dermatologists, and European S3 were reviewed and compared. Practice guidelines from the three dermatological organizations are similar with regards to treatment dosage and initiation but differ in their recommendations for baseline screening and interval laboratory monitoring, treatment in patients undergoing surgery or receiving live vaccines, and treatment contraindications. Ustekinumab is an effective and well-tolerated systemic treatment for patients with psoriasis and should be considered in the line of therapy that dermatologists discuss with their patients. Consideration should be given to evidence-based practice guidelines of global dermatology organizations to effectively guide treatment decisions in patients with psoriasis.
本综述旨在比较和对比全球皮肤科组织针对使用乌司奴单抗治疗银屑病的循证临床实践指南。对美国皮肤病学会、国家银屑病基金会、英国皮肤病学会和欧洲 S3 的临床实践指南进行了回顾和比较。这三个皮肤科组织的实践指南在治疗剂量和起始方面相似，但在基线筛查和间隔实验室监测、手术或接受活疫苗患者的治疗以及治疗禁忌症方面的建议有所不同。乌司奴单抗是一种有效且耐受性良好的系统性治疗药物，适用于银屑病患者，应在皮肤科医生与患者讨论的治疗方案中考虑。应考虑全球皮肤科组织的循证实践指南，以有效地指导银屑病患者的治疗决策。
